Based on CRISPR-Cas9 technology, Wan et al. designed and synthesized a hyaluronic acid (HA)-decorated phenylboronic dendrimer (HAPD) to target APC and KRAS mutations by delivering Cas9 ribonucleoprotein (RNP) for the treatment of CRC. Here, KRAS is linked to colorectal carcinoma.